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Abstract
Introduction: Cardiovascular disease (CVD) is the leading cause of death in patients with inflammatory polyarthritis
(IP), especially in seropositive disease. In established rheumatoid arthritis (RA), insulin resistance (IR) is increased and
associated with CVD. We investigated factors associated with IR in an inception cohort of patients with early IP.
Methods: Patients with early IP (two or more swollen joints for four or more weeks), aged 18 to 65 years, seen
within 24 months of symptom onset were recruited from the Norfolk Arthritis Register (NOAR), a primary-care-
based inception cohort. Assessment included joint examination, current and prior therapy and completion of the
Health Assessment Questionnaire. Fasting blood was taken for measurement of CVD risk factors, rheumatoid factor
(RF), anti-citrullinated protein antibodies (ACPA), C-reactive protein (CRP), and insulin levels. IR was calculated using
the homeostatic model assessment (HOMA-IR). We examined factors associated with IR using univariate and
multivariable linear regression models.
Results: A total of 196 patients, including 59 (30%) males, were studied with a median (interquartile range, IQR)
age and IP symptom duration of 49 (40 to 57) years and 6.7 (4.6 to 10.7) months, respectively. After age and
gender adjustment, HOMA-IR was associated with obesity, (b-Coefficient (95% CI); 1.60 (0.96, 2.24)), higher systolic
and diastolic blood pressure (0.03 (0.01, 0.05) and 0.04 (0.01, 0.08) respectively), triglycerides (1.06 (0.54, 1.57)), and
HDL (-1.38 (-2.17,-0.58)). HOMA-IR was associated with serological status and this association persisted after
adjustment for classic CVD risk factors and other IP-related variables (RF b-Coefficient (95% CI); 0.87 (0.20, 1.53) and
ACPA b-Coefficient (95% CI); 1.42 (0.70, 2.15)).
Conclusions: Seropositivity for RF or ACPA was associated with IR in this early IP cohort. This association may, in
part, explain why seropositive patients have excess CVD mortality.
Introduction
Cardiovascular disease (CVD) remains the leading cause
of death in patients with inflammatory polyarthritis (IP)
and is particularly associated with seropositive disease
[1-4]. Insulin resistance (IR) is known to be increased in
patients with established RA [5,6] and has been shown
to be a risk factor for both clinical CVD [7] and
subclinical atherosclerosis [8-10]. It remains unclear,
however, whether IR occurs early in the course of IP or
whether it develops later in the disease as a consequence
of drug therapy, especially steroid exposure, physical
inactivity or changes in body habitus, such as increased
body fat:muscle ratio.
Established risk factors for IP development include
smoking and obesity, both of which are also risk factors
for CVD and have been associated with IR in the gen-
eral population. It is, therefore, reasonable to consider
whether IR relates primarily to these factors rather than
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to the inflammatory disease process per se [11]. There is
also evidence that the association of IR with established
RA may be mediated through the effects of systemic
inflammation and/or glucocorticoid therapy [12]. Reduc-
tion in inflammatory biomarkers via glucocorticoid ther-
apy, disease modifying anti-rheumatic drugs (DMARDs),
anti-tumour necrosis factor (TNF)-a therapy or weight
loss have all been associated with improvement in IR in
RA [13-17]. It is, therefore, difficult to fully determine
the direction of any associations found in established
RA and what the key factor(s) related to IR are in this
population.
The aim of this study, therefore, was to investigate the
prevalence of IR in patients with early IP and to deter-
mine whether IR was associated with IP-related factors.
In particular we were interested in examining if IR was
related to inflammatory disease burden, serological sta-
tus or early therapy exposure.
Materials and methods
Setting
The Norfolk Arthritis Register (NOAR) recruits indivi-
duals aged 16 years or older at symptom onset, who
have swelling of at least two joints persisting for at least
four weeks. Patients are notified to NOAR by primary
care physicians or hospital rheumatologists in the catch-
ment area [18]. A subset of consecutive patients
recruited between January 2004 and December 2008 by
the main NOAR cohort were also enrolled into this
CVD sub-study if they were 18 to 65 years old and
assessed within 24 months of joint symptom onset.
Informed consent was obtained from patients and Nor-
folk Research Ethics Committees approval.
Manifestations of inflammatory polyarthritis
At inclusion into the NOAR cohort, patients were inter-
viewed by a research nurse. Current and previous medi-
cations for IP, as well as start and stop dates, were
established. Patients were considered to have been
exposed to a therapy if they reported any current or
prior use. Fifty-one joints were assessed for the presence
of swelling and tenderness. Fasting blood was collected,
separated and frozen at -80°C in Norfolk before being
transported to the Arthritis Research UK Epidemiology
Unit in Manchester, UK, for further analysis. A Hitachi
(BMG Labtech LTD, Aylesbury, UK) 917/911 automated
analyser was used to determine C-reactive protein
(CRP) concentration. The rheumatoid factor (RF) was
measured using a particle enhanced immunoturbidi-
metric assay where > 40 iU/ml was considered positive
for RF (Orion Diagnostica, BMG Labtech LTD, Ayles-
bury, UK). Antibodies to citrullinated protein antigens
(ACPA) were measured using the Axis-Shield DIASTAT
kit (Axis-Shield, Dundee, UK) where > 5 U/ml was
considered positive for ACPA. The 28-joint Disease
Activity Score (DAS28) was calculated based on 28 ten-
der joint count, 28 swollen joint count, CRP and visual
analogue scale (VAS) for general well-being [19]. The
UK version of the Health Assessment Questionnaire
(HAQ) was completed by the patient [20]. The 1987
American College of Rheumatology (ACR) classification
criteria for RA were applied [21].
Cardiovascular risk factors
Patients were classified as never smokers, previous smo-
kers (if they had stopped smoking prior to the interview)
or current smokers. Measurement of height and weight
was carried out to calculate body mass index (BMI). Indi-
viduals were classified as being obese if their BMI was ≥
30 kg/m2. Diabetes was considered to be present if
patients reported a physician diagnosis of diabetes, if they
were on treatment for diabetes, or if their fasting blood
glucose was ≥ 7.1 mmol/L on the day of assessment.
Total cholesterol, high density lipoprotein (HDL) and tri-
glycerides were assayed on fresh fasting serum using
CHOD-PAP, a homogenous direct method (Abbott Diag-
nostics, Berkshire, UK) and GPO-PAP methods respec-
tively in Norfolk. LDL levels were mathematically derived
from the total cholesterol and HDL values.
Insulin resistance
Serum insulin levels were analysed using an ELISA kit
from DRG diagnostics (Immunodiagnostic Services, Bol-
don, UK) on fasting frozen serum samples in Manche-
ster. Serum insulin was measured by sensitive ELISA
(Immunodiagnostic Systems Ltd, Boldon, UK). The kit
employs a monoclonal antibody to human insulin,
which shows no cross-reactivity to proinsulin. Insulin
standards were calibrated against the World Health
Organisation (WHO) international reference preparation
66/304. The analytical sensitivity of the assay was 1.76
mIU/L and intra and inter assay coefficients of variation
were < 3.0% and < 6.0% respectively. The manufacturer’s
reference range in apparently normal people is 2 to 25
mIU/L. Insulin resistance was calculated using the
Homeostasis Model Assessment, a model which allows
derivation of insulin resistance (HOMA-IR) and pan-
creatic beta cell function (HOMA-B), calculated from
fasting insulin/glucose pairs using homeostasis model
assessment software, HOMA2, downloaded from the
Diabetes Trials Unit, University of Oxford. This is an
algorithm modified from the original by Jonathan Levy
(Ref. Levy JC, Matthews DR and Hermans MP. Correct
Homeostasis Model Assessment (HOMA) Evaluation
uses the computer program Diabetes Care 1998,
21:2191-2192) IR was defined using the homeostatic
model assessment (HOMA-IR): (Fasting insulin μU ×
Fasting glucose mmol/ml)/22.5.
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Patients with a HOMA-IR value of ≥ 2.29 were classi-
fied as having IR as recommended in the literature [22].
Statistical analysis
The baseline characteristics of patients with normal IR
levels and patients with high IR levels were compared.
For continuous variables, histograms were examined to
ascertain if the variables were normally distributed. A t-
test and Mann-Whitney U tests were used accordingly
to compare demographic and clinical characteristics.
Categorical variables were compared using the c2 test.
Linear and logistic regression analyses, with adjustment
for age and gender, were used to assess the association
between the various traditional risk factors (TRFs) for
CVD and IP related parameters with HOMA-IR and IR
respectively. Linear and logistic regression was used to
assess the association between RF and HOMA-IR and
IR status as a binary variable, respectively. This was
repeated for ACPA. Four groups were identified accord-
ing to their serological status, that is: 1) negative for
both RF and ACPA, 2) RF positive only, 3) ACPA posi-
tive only and 4) positive for both RF and ACPA. Linear
regression using these four categories as the indepen-
dent variable was used to examine the association
between autoantibody status stratified into the above
four categories and IR. All analyses were repeated,
adjusting for the presence of TRFs for CVD and IP
related parameters. The log likelihood test was used to
analyse the degree of difference between the four groups
and their association with IR. All analyses were carried
out using the Stata 10 software package (Stata, College
Station, TX, USA).
Results
Clinical characteristics of the cohort
We studied 196 patients, including 59 (30%) males, with
a median (IQR) age and IP symptom duration of 49 (40
to 57) years and 6.7 (4.6 to 10.7) months respectively.
Baseline characteristics are summarised in Table 1. Of
note, 90 (47%) were RF positive, 66 (34%) were ACPA
positive and 87 (44%) fulfilled 1987 ACR criteria for RA
at baseline. The median (IQR) HOMA-IR was 2.7 (1.8
to 3.9) in the entire cohort and 118 (60%) were insulin
resistant (HOMA-IR ≥ 2.29). Patients with IR had a
higher prevalence of obesity, higher blood pressure and
triglyceride levels and lower HDL levels. A higher pro-
portion of insulin resistant patients were RF or ACPA
positive (Table 1).
Factors associated with insulin resistance
In an age and gender adjusted linear regression analysis,
HOMA-IR was significantly associated with a number of
established cardiovascular and metabolic factors includ-
ing obesity, systolic and diastolic blood pressure,
triglyceride levels and HDL. These associations were
also seen when we considered IR as a dichotomous out-
come (Table 2).
HOMA-IR was associated with tender joint counts,
and HAQ score (b-Coefficient (95% CI); 0.029 (0.002,
0.056) and 0.709 (0.237, 1.182), respectively). In addi-
tion, patients who were seropositive for RF or ACPA
had a significantly higher HOMA-IR score (b-Coefficient
(95% CI); 0.924 (0.254, 1.594) and 1.051 (0.336, 1.767)
respectively) and were more likely to be insulin resistant
(Table 2). The association between RF and ACPA status
and HOMA-IR remained after adjustment and/or
removal of patients with known diabetes mellitus, those
already taking DMARD or steroid therapy, and after
adjustment for other CVD risk factors and IP-related
factors examined (fully adjusted b-Coefficient (95% CI)
for RF = 0.867 (0.204, 1.530) and ACPA = 1.423 (0.701,
2.146) respectively).
Both RF and ACPA status were associated with
HOMA-IR. In the small number of patients positive for
only RF or ACPA (15% and 3% respectively) there was
no association with HOMA-IR. However, there was a
significant association between being positive for both
RF and ACPA and HOMA-IR (Table 3). Patients with
both RF and ACPA had a significantly stronger associa-
tion with HOMA-IR than the RF positive group (log
likelihood test (P = 0.0061) (Table 3).
One hundred (51%) patients were seropositive for RF
or ACPA. Examination of this subset revealed similar
associations with IR as was observed in the whole
cohort including a significant association between
HOMA-IR and tender joint counts and HAQ score (b-
Coefficient (95% CI); 0.049 (0.004, 0.094) and 0.780
(0.071, 1.489), respectively) but not DAS28 score, CRP
or swollen joint counts.
Discussion
In this cohort of patients with IP we have found a sig-
nificant association between serological status (RF and
ACPA) and insulin resistance measured as HOMA-IR.
This association persists after adjustment for classic car-
diovascular risk factors and other IP-related factors. As
far as we are aware, this is the first time this observation
has been noted in an early IP population.
A number of previous studies have examined IR in the
context of established RA, usually drawn from hospital
cohorts. These studies have demonstrated increased IR
in RA [7,23]. Most studies have demonstrated that insu-
lin levels are associated with other metabolic factors
generally clustered within the Metabolic Syndrome
[9,24]. The association between therapy (steroids in par-
ticular) and insulin levels has, however, been controver-
sial [23,25,26]. There is, however, evidence that IR may
be related to inflammatory disease burden [27]. This
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association has been supported by observations of
reduced insulin resistance following control of disease
with anti-TNF therapy [15,16]. With regard to clinical
outcomes, insulin resistance in RA has been associated
with both subclinical atherosclerosis and clinical cardio-
vascular disease [7,28,29]. Given that most study series
of RA patients will have a very high percentage who are
seropositive, it may not be surprising that the associa-
tion we have described in our study has not been
observed in these contexts. In addition, several previous
studies did not report ACPA status. Our previous
studies have demonstrated that seropositivity is an
important prognostic factor in patients with IP and we
have shown that it is in this subgroup that there is a
particular excess of CVD mortality [1,2,4].
In our cohort, IR was associated with the typical pat-
tern of metabolic changes expected from other popula-
tion studies. Higher levels of IR are associated with
obesity, fasting blood glucose, blood pressure, triglycer-
ides and low HDL. We also found a clear and consistent
association between seropositivity for RF and ACPA
with IR, whether this was measured across the range of
Table 1 Characteristics of 196 patients with recent onset IP and in those with and without IR
Variable at baseline All pts
n = 196
IR
(HOMA IR ≥ 2.29)
n = 118 (60%)
No IR
HOMA IR < 2.29
n = 78 (40%)
P-value
Age when first seen (years) † 49 (40 to 57) 49 (41 to 56) 48 (37 to 57) 0.49
Male gender 59 (30%) 38 (32%) 21 (27%) 0.43
Current smoker 50 (26%) 27 (23%) 23 (29%) 0.30
Obese (BMI ≥ 30) 57 (30%) 46 (40%) 11 (15%) < 0.001
On treatment for or diagnosed with DM 26 (13%) 16 (14%) 10 (13%) 0.88
Fasting blood glucose (mmol/L) * 4.7 (4.4 to 5.0) 4.8 (4.5 to 5.1) 4.5 (4.3 to 4.8) < 0.001
Fasting insulin (μU) 12.7 (8.9 to 18.1) 16.7 (13.2 to 21.6) 8.2 (6.0 to 9.4) < 0.001
HOMA-IR 2.7 (1.8 to 3.9) 3.5 (2.8 to 4.8) 1.6 (1.2 to 1.9) < 0.001
SBP (mmHg) * 132 (17) 135 (17) 129 (15) 0.04
DBP (mmHg) * 81 (10) 83 (10) 79 (9) 0.01
On treatment for hypertension 19 (10%) 13 (11%) 6 (8%) 0.44
TG (mmol/L) * 1.4 (0.6) 1.6 (0.6) 1.1 (0.5) < 0.001
T.Chol (mmol/L) * 5.4 (1.1) 5.5 (1.1) 5.2 (1.1) 0.24
HDL (mmol/L) * 1.5 (0.4) 1.5 (0.5) 1.6 (0.4) 0.03
LDL (mmol/L) * 3.2 (0.9) 3.3 (0.9) 3.1 (0.9) 0.43
On statin treatment 11 (6%) 5 (4%) 6 (8%) 0.30
IP symptom duration (months)† 6.7 (4.6 to 10.7) 6.5 (4.5 to 9.9) 7.0 (4.7 to 11.8) 0.28
Age at IP symptom onset 48 (40 to 56) 48 (40 to 55) 48 (36 to 57) 0.42
RF positive 90 (47%) 63 (55%) 27 (35%) 0.01
ACPA positive 66 (34%) 50 (44%) 16 (21%) < 0.001
Fulfil ACR criteria for RA 87 (44%) 58 (49%) 29 (37%) 0.10
Swollen joint count (/51)† 4 (1 to 7) 4 (2 to 9) 4 (1 to 7) 0.44
Tender joint count (/51)† 8 (2 to 18) 8 (2 to 18) 9 (3 to 17) 0.87
Both swollen & tender (/51)† 2 (0 to 6) 2 (0 to 6) 2 (0 to 5) 0.96
CRP (mg/L)† 10 (7 to 17) 11 (5 to 21) 9 (7 to 13) 0.21
DAS28CRP
† 3.9 (3.0 to 4.8) 3.9 (3.0 to 4.9) 3.9 (3.1 to 4.7) 0.73
HAQ† 0.88 (0.38 to 1.38) 0.88 (0.38 to 1.68) 0.88 (0.38 to 1.38) 0.26
On steroids
prior to baseline assessment
43 (22%) 24 (20%) 19 (24%) 0.51
On DMARDs
prior to baseline assessment
105 (54%) 67 (57%) 38 (49%) 0.27
On MTX prior to baseline assessment 60 (31%) 36 (31%) 24 (31%) 0.97
On HCQ prior to baseline assessment 11 (6%) 6 (5%) 5 (6%) 0.69
All data are presented as n (%) except where we indicate that either median (IQR) † or mean (SD) * were used.
ACPA, anti-CCP antibody; ACR, American College of Rheumatology; CRP, C-reactive protein; DAS 28CRP , Disease Activity Score calculated using CRP; DBP, diastolic
blood pressure; DM, diabetes mellitus; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; HDL, high density lipoprotein; HOMA-IR, Homeostatic
Model Assessment for Insulin Resistance; IP, inflammatory polyarthritis; LDL, low density lipoprotein; MTX, methotrexate; RF, rheumatoid factor; SBP, systolic blood
pressure;
T.chol, total cholesterol; TG, triglycerides
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HOMA-IR or if we treated IR as a categorical outcome.
With regard to other IP-related parameters, we did find
that higher levels of HOMA-IR were associated with
tender joint counts and HAQ score at baseline; however,
the lack of association with DAS28 scores, swollen joint
counts and acute phase reactants argues against a strong
influence of inflammatory disease burden in this cohort.
Previous general population studies have also shown
that TNF-a and IL-6 are increased in insulin resistant
states [30,31]. TNF-a is known to interfere with both
glycaemic sensing and insulin signalling, thus impairing
glucose handling [31]. The observation by others that
TNF blockade reduces IR, would also support the
hypothesis that inflammatory disease burden contributes
to IR in IP [32]. Our data, however, suggest that serolo-
gical status may be a dominant factor determining levels
of IR in inflammatory polyarthritis patients.
While severe insulin resistance secondary to insulin
receptor antibodies in the context of type I diabetes
mellitus is widely recognized [33], there are limited pub-
lished data describing the association of insulin resis-
tance with other autoantibodies. RA and its related
conditions overlap with other autoimmune conditions
and affect many organs. It is possible that the same trig-
gers to autoimmune RF and ACPA production also con-
tribute to insulin receptor antibodies sufficient to induce
the degree of insulin resistance that we see in our study.
We note a higher level of insulin production and, there-
fore, islet cell destruction is unlikely to be the mechan-
ism by which this insulin resistance is induced.
We did not find any significant contribution of ther-
apy to IR in our cohort. However, in this early cohort
only 22% of patients were exposed to steroids by the
time of the study and 54% of patients had been recently
Table 2 Associations between traditional cardiovascular disease risk factors, IP related factors and insulin resistance
after adjustment for age and gender
Variable Dependent variable †
HOMA-IR (continuos) ▲
(b-Coefficient (95% CI))
IR* (HOMA-IR > 2.29)#
(Odds ratio (95% CI))
Age at time of study (per year) 0.018 (-0.012, 0.048) 1.02 (0.99, 1.04)
Male gender 0.044 (-0.665, 0.753) 1.27 (0.67, 2.39)
Current smoker 0.004 (-0.747, 0.755) 0.71 (0.37, 1.37)
Obese (Y/N) 1.602 (0.963, 2.240) 4.02 (1.91, 8.50)
SBP (per mmHg) 0.029 (0.007, 0.050) 1.02 (1.00, 1.04)
DBP (per mmHg) 0.043 (0.009, 0.077) 1.04 (1.01, 1.08)
TG (per mmol/L) 1.057 (0.542, 1.572) 3.95 (2.09, 7.46)
T.Chol (per mmol/L) 0.155 (-0.162, 0.472) 1.19 (0.90, 1.59)
HDL (per mmol/L) -1.375 (-2.172, -0.578) 0.44 (0.21, 0.92)
LDL (per mmol/L) 0.193 (-0.169, 0.556) 1.11 (0.80, 1.53)
DM (On treatment for DM/DM/fasting glucose ≥ 7.1 mmol/L) -0.114 (-1.170, 0.942) 0.73 (0.29, 1.82)
IP disease duration (per month) -0.001 (-0.003, 0.001) 1.00 (1.00, 1.00)
RF positive 0.924 (0.254, 1.594) 2.20 (1.20, 4.06)
ACPA positive 1.051 (0.336, 1.767) 3.00 (1.51, 5.96)
ACR criteria for RA 0.542 (-0.114, 1.198) 1.62 (0.90, 2.93)
Swollen joint (per joint) 0.032 (-0.016, 0.080) 1.03 (0.98, 1.07)
Tender joint (per joint) 0.029 (0.002, 0.056) 1.01 (0.99, 1.04)
CRP (per mg/L) 0.007 (-0.012, 0.026) 1.00 (0.99, 1.02)
DAS28 0.168 (-0.100, 0.437) 1.05 (0.83, 1.34)
HAQ 0.709 (0.237, 1.182) 1.41 (0.91, 2.19)
On steroids prior to baseline assessment -0.300 (-1.094, 0.493) 0.74 (0.37, 1.48)
On DMARDs prior to baseline assessment 0.533 (-0.124, 1.190) 1.31 (0.73, 2.34)
On MTX prior to baseline assessment 0.277 (-0.435, 0.989) 0.94 (0.50, 1.76)
On HQC prior to baseline assessment -0.218 (-1.636, 1.200) 0.81 (0.24, 2.79)
▲Linear regression producing b-coefficients were used for continuous outcome. b-coefficients are considered statistically significant if their 95% CI values do not
include zero. #Logistic regression producing odds ratios used for binary outcomes. Odds ratios are considered significant if the 95% CI values do not include 1. †
(adjusted for age and gender)
ACPA, anti-CCP antibody; ACR, American College of Rheumatology; BMI, body mass index; CRP, C-reactive protein; DAS, Disease Activity Score; DBP, diastolic
blood pressure; DM, diabetes mellitus; DMARDs, disease modifying anti-rheumatic drugs; HAQ, Health Assessment Questionnaire; HCQ, hydroxychloroquine; HDL,
high density lipoprotein; IP, inflammatory polyarthritis; LDL, low density lipoprotein; MTX, methotrexate; RF, rheumatoid factor; SBP, systolic blood pressure; T.
Chol, total cholesterol; TG, triglycerides.
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started on DMARD therapy. DMARDs may of course
reduce IR through anti-inflammatory effects, and this
may also even be true of low-dose steroid therapy [34].
We plan to follow this cohort to determine whether
therapy does play a role in influencing the metabolic
status of these patients over time.
Most of the association between serological status
and IR remains unexplained in our fully adjusted mod-
els. We also note that the association was particularly
strong in those who are positive for both antibodies,
although it should be pointed out that this was the
majority of seropositive patients. RF and ACPA are
associated with the presence of the shared epitope, and
can be positive for many years prior to the onset of
arthritis. From a prognostic viewpoint, seropositivity
also predicts future cardiovascular mortality risk
[35,36]. Seropositive patients are also more likely to
develop extra-articular features such as nodules, lung
disease and vasculitis [37-39]. Other groups have
found evidence for endothelial cell activation and dys-
function in seropositive patients [40,41] and in RA
patients who carry the shared epitope [42]. Insulin
resistance, therefore, may be a consequence of early
endothelial dysfunction in seropositive patients. Insulin
stimulates disposal of glucose from the circulation into
skeletal muscle and in eNOS knockout mice, capillary
density is reduced and insulin mediated glucose
clearance is reduced by 40% [43]. Therefore, endothe-
lial dysfunction is hypothesised to be a primary step in
the development of the insulin resistant state.
The development of RF and ACPA has also been asso-
ciated with the shared epitope, and with smoking status
[1,44,45]. In addition, we have previously found that
obesity is a risk factor for developing IP [46]. An alter-
native explanation for the observations found is that
smoking and obesity contribute to both the IR and sero-
positivity in the population at risk of developing IP.
Although our study looked at patients early in the
course of IP, ultimately this question can only be
answered in a pre-symptomatic population as we cannot
accurately determine which came first in this
population.
There are several limitations which should be consid-
ered in this study. First, our study is limited by its
cross-sectional nature and longitudinal studies are
required to examine in closer detail the temporal and
causal relationship between adiposity, classic risk factors
for CVD, inflammatory joint disease and therapy on the
development of IR. Conversely, by examining this ques-
tion in a community-based, early IP population, we have
noted an important association between serological sta-
tus and IR. Secondly, the limited number of patients did
not allow for further stratification of our results, in par-
ticular with regard to the dose and cumulative exposure
of oral steroid therapy and its associations with IR. A
further limitation is that we did not have the facilities in
a community-based study to undertake hyperinsulinae-
mic euglycaemic clamp experiments, which are the ‘gold
standard’ for ascertaining IR levels [22]. The HOMA-IR
has, however, been validated as being an appropriate
alternative from a blood sample collected from our
patients in their own home [47]. Multiple testing using
both HOMA-IR as a continuous variable and IR as a
binary variable may be an issue. Whilst HOMA-IR may
be considered more statistically valid, the use of IR as a
binary variable is more clinically useful and so both out-
comes are presented here, with results that were consis-
tent using both approaches.
Conclusions
In conclusion, we have found that in an early IP popula-
tion, IR is associated with the presence of RF and
ACPA, an effect that persists after adjustment for meta-
bolic and other IP-related factors. Insulin resistance is,
therefore, detectable early in the course of IP and may,
in part, explain the excess CVD risk observed in seropo-
sitive patients. A better understanding of the mechan-
isms underlying this observation may shed light on the
pathogenesis of accelerated atherosclerosis in IP
patients.
Table 3 Associations between rheumatoid factor and
anti-CCP antibodies with insulin resistance alone and in
combination with one another after serial adjustment
Variable Numbers of
patients
Association with HOMA-IR
TRF & IP risk factor
adjusted IR
b-Coefficient OR (95% CI) #
RF +ve * 90 (47%) 0.867 (0.204, 1.530)
ACPA +ve * 66 (35%) 1.423 (0.701, 2.146)
RF-ve/ACPA -ve 96 (49%) 0
RF +ve/
ACPA -ve †
29 (15%) -0.015 (-0.973, 0.944)
ACPA+ve/
RF -ve†
6 (3%) 0.932 (-0.898, 2.763)
Both RF+ve/ACPA
+ve †
60 (31%) 1.472 (0.695, 2.250) √
* = Seropositive vs. seronegative for RF and ACPA (n = 193 and 191,
respectively)
† = Patients stratified into four groups depending on autoantibody status and
compared with other groups (n = 191)
√ = Model significantly different in patients positive for both RF and ACPA
relative to those RF positive only (P = 0.0061) with age and gender and other
parameters adjusted.)
▲Linear regression producing b-coefficients were used for continuous
outcome. b-coefficients are considered statistically significant if their 95% CI
values do not include zero.
#Logistic regression producing odds ratios used for binary outcomes. Odds
ratios are considered significant if the 95% CI values do not include 1.
ACPA, anti-CCP antibody; IP, inflammatory polyarthritis; RF, rheumatoid factor.
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